Tirzepatide vs Semaglutide 2026: Which GLP-1 Is Right for You?

Both are GLP-1 medications and both produce significant weight loss. But they are not the same drug. Here is an honest comparison of tirzepatide and semaglutide — what the clinical data shows, what the side effects are, and which one is better suited to your situation.

By Matthew IrvingPublished May 14, 2026Updated May 14, 2026

Quick verdict

  • Stronger results: Tirzepatide. Clinical trials show 20–22% average body weight loss vs ~15% for semaglutide.
  • Longer track record: Semaglutide. More years of real-world data and a well-understood side effect profile.
  • More affordable: Semaglutide. Compounded semaglutide is typically $50–100/month cheaper than tirzepatide.
  • Bottom line: If you want maximum weight loss and cost is not the deciding factor, tirzepatide has the edge. If you prefer a proven medication at a lower price, semaglutide is excellent.

Medical disclaimer

This article is for informational purposes only. Both tirzepatide and semaglutide are prescription medications. Always consult a licensed healthcare provider before starting any weight loss medication. TelehealthPick does not provide medical advice.

How Each Drug Works

Both medications are injectable once-weekly drugs that reduce appetite and slow digestion — but they achieve this through different mechanisms.

Semaglutide (Ozempic / Wegovy)

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after eating — it signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar. Semaglutide mimics this hormone in a more potent and sustained way than your body produces on its own, dramatically reducing appetite and caloric intake over time.

Tirzepatide (Mounjaro / Zepbound)

Tirzepatide is a dual GLP-1/GIP receptor agonist. In addition to GLP-1, it also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone involved in fat storage, insulin regulation, and energy metabolism. Targeting both pathways simultaneously produces a stronger appetite-suppressing effect than GLP-1 alone — which is reflected in the larger average weight loss seen in tirzepatide trials.

In plain terms

Semaglutide turns down one appetite dial. Tirzepatide turns down two. Both significantly reduce hunger — tirzepatide just has a slightly bigger effect for most people.

Clinical Results Compared

The best head-to-head data comes from two large randomised controlled trials — STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) — both run over 68–72 weeks in adults with obesity.

Semaglutide — STEP-1 trial

  • Average weight loss: ~15% of body weight
  • 5% loss achieved: 86% of participants
  • 15% loss achieved: 32% of participants
  • Dose: 2.4mg weekly

Tirzepatide — SURMOUNT-1 trial

  • Average weight loss: 20–22% of body weight
  • 5% loss achieved: 91% of participants
  • 20% loss achieved: 57% of participants
  • Dose: 10–15mg weekly

The difference is meaningful but not dramatic in practical terms. Someone weighing 220 lbs on semaglutide might lose around 33 lbs on average; the same person on tirzepatide might lose 44–48 lbs. Both are significant — tirzepatide just tends to produce more.

It is worth noting that these are averages from clinical trials. Individual results vary significantly based on starting weight, diet, activity level, and how well you tolerate dose escalation. Some people achieve far above-average results on semaglutide; some do not respond as strongly to tirzepatide as the trials suggest.

Side Effects

Both medications share a very similar side effect profile. The most common effects relate to the GI tract and typically peak during dose escalation before improving as your body adjusts.

Side effectSemaglutideTirzepatide
NauseaVery common, especially earlyVery common, especially early
VomitingCommon during escalationCommon during escalation
DiarrheaCommonCommon
ConstipationCommonCommon
FatigueModerateModerate
Injection site reactionMild, occasionalMild, occasional
Reduced appetiteSignificantSignificant — often stronger
Muscle lossSome (manageable with protein)Some (manageable with protein)

The most effective way to manage side effects is to start at the lowest dose and increase slowly. Most telehealth platforms use a titration schedule — typically 4 weeks at each dose level — that gives your body time to adjust before escalating. Do not rush titration in pursuit of faster results.

Side-by-Side Comparison

FactorSemaglutideTirzepatide
MechanismGLP-1 receptor agonistGLP-1 + GIP dual agonist
Branded name (weight loss)WegovyZepbound
Average weight loss (trials)~15% body weight20–22% body weight
Years of data5+ years3+ years
DosingOnce weekly injectionOnce weekly injection
Compounded cost (telehealth)From ~$150/monthFrom ~$199/month
Side effectsNausea, GI symptomsNausea, GI symptoms (similar)
Availability via telehealthWidely availableWidely available
Insurance coverageLimitedLimited

Who Each Medication Suits

Choose semaglutide if you:

  • Want the most established medication with the most data
  • Are cost-conscious and want the most affordable compounded option
  • Have a moderate amount of weight to lose (under 50 lbs)
  • Have been sensitive to new medications in the past
  • Want to start with a lower-intensity option

Choose tirzepatide if you:

  • Want the strongest available results
  • Have significant weight to lose (50+ lbs)
  • Have tried semaglutide without enough response
  • Have type 2 diabetes or insulin resistance alongside obesity
  • Are in perimenopause/menopause and dealing with hormonal weight gain

Cost and Availability

Branded semaglutide (Wegovy) and tirzepatide (Zepbound) both list at over $1,000/month without insurance. Insurance coverage for weight loss medications remains patchy — many plans do not cover them at all.

Compounded versions through telehealth are dramatically cheaper. Compounded semaglutide typically starts at $150–250/month; compounded tirzepatide at $199–350/month. Prices vary by platform, dose, and whether you are on a monthly or quarterly plan. Quarterly plans are usually cheaper per month.

None of the major telehealth platforms accept insurance for compounded GLP-1 medications. Some accept FSA/HSA payments — ShedRx explicitly accepts FSA/HSA, which can reduce your effective out-of-pocket cost significantly if you have one.

Getting Either Medication Online

Both semaglutide and tirzepatide are available through telehealth as compounded medications. The process is the same regardless of which you choose: complete an online health intake form, a licensed provider reviews it and issues a prescription if appropriate, and the medication is shipped directly to you. No in-person appointment or video call is required on most platforms.

The telehealth platforms on this site that offer both options include ShedRx (which also accepts FSA/HSA) and Sprout Health (one of the most affordable options for semaglutide starting at $149/month).

Compare GLP-1 platforms side by side

See all available providers, pricing, and which offers tirzepatide vs semaglutide on our GLP-1 hub.

Compare GLP-1 providers →

Frequently Asked Questions